Insulet Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Insulet Corp. (PODD) shares rose 1.19% to $142.85 on Monday, marking its third consecutive day of gains despite a broader market decline. However, the stock underperformed compared to key competitors like Eli Lilly, DexCom, and Johnson & Johnson, which all posted stronger daily increases. Insulet remains significantly below its 52-week high of $354.88.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Insulet Corp. (PODD) advanced 1.19% to $142.85 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.06% to 7,753.11 and Dow Jones Industrial Average falling 0.11% to 53,975.98.

This was the stock's third consecutive day of gains.

Insulet Corp. closed 59.75% below its 52-week high of $354.88, which the company achieved on November 20th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Eli Lilly & Co. (LLY) rose 3.90% to $1,231.94, DexCom Inc. (DXCM) rose 3.42% to $87.65, and Johnson & Johnson (JNJ) rose 0.99% to $261.81.

Data source: Dow Jones Market Data, FactSet. Data compiled August 10, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

08-10-26 1719ET

Source: MarketWatch Automated The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.